Author: Ryan Allway

VANCOUVER , Feb. 27, 2018 /CNW/ – Friday Night Inc. (the Company or Friday Night) (CSE:TGIF) (1QF.F) (TGIFF) is pleased to provide an update on its 91% owned subsidiary, Infused MFG. (“Infused”) and the Canna Hemp Brand.

View photos

More

Infused’s Canna Hemp brand has seen strong demand in the California market since the state level legalization on January 1 ^st 2018.  The California cannabis market is currently estimated to be worth $8.5 Billion dollars .

Canna Hemp products are now selling in 15 retail locations in California and Infused has recently engaged 2 additional sales representatives to expand on their distribution network.

After careful review of the evolving Las Vegas market and the success in the California market, the Company has decided to indefinitely postpone the spin-out of Infused MFG. Management believes Infused and the Canna Hemp brand will continue to show strong growth and success in new markets and will provide value to the shareholders of Friday Night.

The Company also announced that 1,300,000 stock options were issued to advisors and a director pursuant to the terms of the Company’s stock option plan.  These options are exercisable at $0.65 for a period of 5 years.

About Friday Night Inc. 

Friday Night Inc. is a Canadian public company, which owns and controls cannabis and hemp-based assets in Las Vegas Nevada.  The company owns 91% of Alternative Medicine Association, LC (AMA), a licensed medical and adult-use cannabis cultivation and production facility that produces its own line of unique cannabis-based products and manufactures other third-party brands.  Infused MFG, also a 91% owned subsidiary, produces hemp-based, CBD products, thoughtfully crafted of high quality organic botanical ingredients.  Friday Night Inc. is focused on strengthening and expanding these operations within and outside of the state.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.   Friday Night undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law or the Canadian Securities Exchange.

The post Friday Night Inc. Provides Update on Infused and California Expansion appeared first on CannabisFN.

VANCOUVER, British Columbia, February 27, 2018 /PRNewswire/ —

Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE: ATT) (ATT.CN) (ATTBF) is pleased to announce that it has entered into a definitive agreement (the “Definitive Agreement“) to acquire (the “Acquisition“) a 90% ownership interest in Gabriola Green Farms Inc. (“Gabriola“).

Gabriola is a privately held British Columbia company that has applied for a license to produce (an “LP“) under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“) on Gabriola Island, one of the gulf islands located in the Strait of Georgia off the coast of British Columbia. Gabriola Island has a consistent temperature and humidity level, which makes it well suited to greenhouse growing.

“This is one of the most significant steps our Company has taken towards becoming a full service cannabis company,” stated Rob Abenante, Abattis President and CEO. “After successfully obtaining a license through Gabriola, we intend to not only cultivate marijuana, but more importantly sell extracted cannabis products, which will complete our full downstream service offerings.”

The Definitive Agreement comes following a series of rapid acquisitions, capital raises, investments and joint-ventures for the Company, which include the acquisition of a cash flowing vaporizer company, investment into a cutting-edge Blockchain technology and cryptocurrency and several collaborations with respected organizations, including the University of British Columbia.

Pursuant to the Definitive Agreement, in exchange for a 90% ownership interest in Gabriola, Abattis will issue an aggregate of 59,760,956 common shares of the Company (each, a “Share“), at a deemed price of $0.3765 per share, and pay an aggregate of $2.5 million in cash to the shareholders of Gabriola, with the exception of CannaNUMUS Blockchain Inc. (“CannaNUMUS“), a company in which Abattis owns a 49% stake, which will retain its 10% ownership stake in Gabriola. In addition, Abattis will make milestone-based payments (the “Milestone Payments“) to such shareholders of Gabriola of (i) $5 million upon Gabriola’s receipt of a cultivation license under the ACMPR and (ii) $5 millionupon Gabriola’s receipt of a sales license under the ACMPR. The Milestone Payments will be satisfied through the issuance of shares. Closing of the acquisition is subject to, among other things, completion of due diligence by Abattis and the receipt of any required consents, including that of the Canadian Securities Exchange.

In connection with the Acquisition, Abattis has also secured (i) a right of first refusal on the remaining 10% ownership interest in Gabriola from CannaNUMUS and (ii) an option to acquire the lands on which Gabriola’s operations are conducted for $7 million until February 27, 2023 from an unrelated third-party.

“Our acquisition of Gabriola will round out our product offerings and complement our existing offerings in the cannabis products, technologies and services space. With its production facility located on ideal Gabriola Island, Gabriola has the potential to become a significant producer upon receipt of an LP,” stated Rob Abenante. “With our powerful cash position and liquidity, as well as our experience across various domains in the cannabis space, we are well positioned to support Gabriola’s expansion”.

About Abattis Bioceuticals Corp. 

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canadaand foreign jurisdictions. For more information, visit the Company’s website at: http://www.abattis.com

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,
“Rob Abenante“
Robert Abenante, President & CEO

The post Abattis Enters Into Definitive Agreement To Acquire Gabriola Green Farms appeared first on CannabisFN.

VANCOUVER, British Columbia, Feb. 27, 2018 (GLOBE NEWSWIRE) — Micron Waste Technologies Inc. (“Micron” or the “Company”) (CSE:MWM) (MICWF) (7FM2.F) today announced that the Company has engaged the services of renowned engineering consultancy, BC Research Inc. to accelerate the commercialization process of its waste digester technology for the cannabis industry.

Micron has developed a new technology, based on aerobic digestion and subsequent treatment, that converts organic waste into clean water that meets municipal effluent discharge standards. The effluent from currently available digester-based treatment systems of organic waste does not meet municipal discharge standards and requires costly further treatment. Many organizations that generate organic waste currently use municipal landfill sites for their organic waste, which is costly and has a negative impact on the environment. The merits of Micron’s technology have been successfully demonstrated with a grocery supermarket chain located in British Columbia, Canada, and Micron has entered into a Memorandum of Understanding with the group to plan for additional installation of Micron’s organic waste digester units at other locations in BC.

Per the Company’s press releases of January 15, 2018 and December 19, 2017, Micron has completed a strategic partnership with Aurora Cannabis for the optimization of the Company’s technology for the cannabis industry. The companies are currently progressing well with the preliminary research towards the installation of the first unit at one of Aurora’s cultivation facilities, anticipated for the second calendar quarter of 2018.

Micron has now engaged the services of renowned engineering consultancy BC Research, which has a strong track record in helping commercialize new technologies. BC Research, which predominantly works with large enterprises on process research, custom engineering, pilot plant services, also provides access to a vertically integrated technology development and commercialization ecosystem.

The work with BC Research, which is conducted in parallel with the Aurora Project, serves to deliver a unit that functions in a broad temperature range, making it suitable for deployment on a global scale in wide range of climates. Furthermore, leveraging BC Research`s deep expertise in commercializing technologies, the project aims to develop a digester unit suitable for mass production.

The new unit, which will form the blue print for subsequent commercial units, will be installed at one of Aurora Cannabis’s cultivation facilities for validation in this particular industry. Micron therefore anticipates accelerating time to market for its technology, enabling the Company to commence penetration of the cannabis sector. The optimization for temperature range will significantly increase the marketability of the technology to a range of other industries.

“We are extremely pleased to be working with BC Research and Aurora Cannabis to develop a market-ready Micron Cannabis Waste Digester,” said Rav Mlait, CEO. “The enhanced features requested by our clients are anticipated to accelerate commercial adoption and make Micron’s technology more attractive to cannabis producers seeking a less costly, more convenient, and “greener” means of handling organic waste. We anticipate that the results from our efforts with Aurora Cannabis will not only accelerate our entry into this sector, but allow us to leverage the results to develop access to large new markets.”

“We are excited to be part of this project.  The potential applicability of Micron’s technology to a wide range of industrial challenges makes it an attractive reason for our organization to be engaged. Tackling some of the cannabis cultivation industry’s needs is an example of where the technology may fit well, and it provides another opportunity to demonstrate the technology in a very different industrial application.”, stated Sergio Berretta, vice president and COO at BC Research. “We look forward to bringing our expertise in commercializing new technologies to the Aurora-Micron project, and are excited about the broader potential of the Micron Waste Digester.”

About BC Research Inc

BC Research Inc. (BCRI), as part of the NORAM family of companies, has a global reputation for innovation and excellence in the supply of proprietary engineering and equipment packages to the chemical, pulp and paper, minerals processing and electrochemical sectors. Their six specialized business groups, with a staff of over 200 professionals, have completed capital projects on five continents. They are recognized worldwide as a leader in the fields of nitration, sulfuric acid and electrochemistry. In addition to carrying out large assignments for major multi-national clients and municipalities, BCRI works with early-stage technology companies. They provide engineering design and fabrication support, sharing their experience in technology commercialization, and growing with companies as a strategic stakeholder.

The post Micron Waste to Accelerate Commercialization of Cannabis Waste Digester appeared first on CannabisFN.

GREENWOOD VILLAGE, CO, Feb. 27, 2018 (GLOBE NEWSWIRE) — Helix TCS, Inc. (HLIX) has begun moving into the California market in support of current and new clients.  As part of its previously mentioned plans to expand nationally, this step marks a significant milestone in the company’s strategic growth.

“Helix TCS continues to execute tightly on its strategic plan, and we intend to grow in the California market with the same speed and success that we’ve had in the Colorado market,” stated Helix CEO Zachary L. Venegas.

Helix has been growing its reach and market share rapidly in the legal cannabis industry, operating in the security, transportation, and compliance sectors.  Recently announced investments in BioTrack THC further support and accelerate its efforts.  

“We continue to hone our service offerings and service delivery to help our customers operate as safely, efficiently, and profitably as possible,” stated Venegas.

About Helix TCS

Helix TCS, Inc. (HLIX) is a premier provider of integrated operating environment solutions for the legal cannabis industry.  Helix provides a proprietary software suite and partnership platform to the legal cannabis industry, helping clients manage inventory and supply costs and bespoke monitoring and transport solutions.  Helix provides clients in the legal cannabis industry high standard security operations, including transportation, armed and unarmed guarding, training, investigation, and special services.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements.  Actual results might differ materially from those explicit or implicit in the forward-looking statements.  Important factors that could cause actual results to differ materially include: our ability to fund our operations and pay any outstanding debt; fluctuations in our financial results; general economic risks; the volatile nature of the market for our products and services and other factors that could impact our anticipated growth; our ability to manage our growth; changes in laws and regulations regarding the cannabis industry and service providers in the cannabis industry; reliance on key personnel; our ability to compete effectively; security and other risks associated with our business; intellectual property risks; and other risk factors set forth from time to time in our SEC filings.  Helix TCS assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

The post Helix TCS, Inc. Begins Moving Into the CA Market appeared first on CannabisFN.

Vancouver, B.C (FSCwire) – Friday Night Inc. (Friday Night) (CSE: TGIF) (FWB: 1QF) (OTCQB: TGIFF) has acquired as a wholly owned subsidiary Spire Secure Logistics Inc. (“Spire”), a Canadian private company specializing in security, intelligence, and compliance with international clients and expertise in both the regulated cannabis industry and other sectors.

Friday Night agreed to acquire 100% of Spire by the issuance of 7,142,857 common shares at a deemed price of $0.70 per share.  Closing is scheduled for March 1, 2018.  Friday Night will allocate working capital of CAD $1,000,000 to expand Spire’s client base in Canada and globally.  The shares issued will be subject to an escrow arrangement that will see 12.5% released from escrow on closing and the remaining 87.5% being released to the vendors in 7 equal tranches of 12.5%, each to be issued on the first day of each quarter of Friday Night’s fiscal year, beginning with May 1, 2018.

About Spire

Spire provides strategic security consulting in Canada, the United States and Latin and South America. They act for or have acted for licensed producers and ancillary businesses in the cannabis sector. Formed almost 3 years ago by Andy Richards and Jeff Meyers, two career law enforcement professionals well acquainted with organized crime and both the illicit and legal cannabis industry, Spire has quickly become a leading firm for companies looking to ensure their operations adhere to government regulations around security and are best equipped to deter the infiltration of organized crime and black market diversion.  Spire is led by experts with international backgrounds in covert and undercover operations to infiltrate and disrupt organized crime, including outlaw motorcycle gangs, cartels, and other violent gangs. Members of the Spire team have been involved with policy, compliance, and law enforcement in the regulated cannabis industry since its earliest days. 

By adding this business to the Company’s portfolio, Friday Night is diversifying its income stream and achieving exposure to international markets.

“The Spire team brings decades of experience in the trenches of law enforcement, security, and high-stakes risk management.” said Brayden Sutton, CEO of Fright Night Inc. “Spire is uniquely equipped to keep companies safe, secure, and compliant – which in turn creates more shareholder value and peace of mind.  I am extremely honored to call the Spire team a part of our family and look forward to the increased level of intelligence and awareness it brings us as a company, whether that be in current operations or when evaluating other opportunities in the sector.”

“Spire works with companies who want to make an honest dollar in a secure, compliant, law-abiding cannabis industry,” said Spire’s CEO Andy Richards, a 34-year law enforcement veteran who has led numerous high-profile investigations of organized drug crime. “Whether it’s regulatory applications, security procedures, or working hand-in-hand with government and law enforcement, our team has the right skills, connections, and experience to deliver.”

Coincident with closing, Andy Richards will join the Friday Night Inc. Board of Directors.

About Andy Richards, CEO

Andy Richards spent 34 years in law enforcement and retired as a Deputy Police Chief in the Greater Vancouver area in 2015.  For over half his career, Andy specialized in complex organized crime investigations and led many successful major projects, most with an international component.  He has a master’s degree in Criminal Justice, remains an associate member of the Canadian Association of Chiefs of Police, and, as a court-recognized expert witness, continues to testify in organized crime cases.

Andy helped build Spire into an industry leader in the high-risk international mining and legal cannabis sectors.

About Jeff Meyers, COO

In addition to recent corporate experience protecting Canadian mining assets in high risk areas of the world, Jeff Meyers brings 24 years of Canadian law enforcement experience specializing in covert operations, organized crime, and cross border regulation, enforcement, and interdiction.  Jeff’s experience and expertise has facilitated the creation of strategic relationships with law enforcement and government officials around the world, including Europe, the United States, and Central and South America.

The post Friday Night Inc. Acquires Spire Secure Logistics Inc. appeared first on CannabisFN.

VICTORIA, British Columbia, Feb. 22, 2018 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (EMH.V) (EMHTF) (“Emerald”) has achieved the #1 ranking in the 2018 TSX Venture 50™ for the clean technology & life science sector and is recognized as a top performing company for the second consecutive year. The TSX Venture 50™ is the TSX Venture Exchange’s annual ranking of Canada’s top 50 emerging publicly traded companies. 

“Emerald, like all the companies in the TSX Venture 50™ and in the rapidly growing cannabis sector, aspires to build a growing and differentiated business that will provide notable value to shareholders. In achieving #1 status in our sector in 2018, I extend a big thank you to our entire team for their effort and our shareholders for their support,” said Chris Wagner, CEO of Emerald. “We are executing very well on our major production expansion projects, are well-financed, and are advancing unique product innovation and marketing initiatives. We believe these factors strongly position Emerald for the anticipated legal adult-use cannabis market in Canada and for emerging international opportunities.”

Winner selections are based on a formula with equal weighting given to share price appreciation, market capitalization growth, and trading volume for the year ending December 31, 2017. The TSX Venture 50™ acknowledges the top 10 performing companies listed on the TSX Venture Exchange in five industry sectors: mining, oil & gas, clean technology & life sciences, diversified industries, and technology.

The TSXV created a video profile on Emerald and other 2018 TSX Venture 50™ winners, available at www.tsx.com/venture50.

Earlier this month Emerald announced that it had been upgraded to Tier 1 on the the TSX Venture Exchange. This status was based on standards regarding historical financial performance, stage of development, and financial resources. Tier 1 is the highest tier of the TSX-V and is reserved for more advanced issuers with greater financial resources.

Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. (EMH.V) (EMHTF) operates through Emerald Health Botanicals Inc. (“Botanicals”), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through Botanicals, Emerald is authorized to produce and sell dried medical cannabis flower and medical cannabis oil. It currently operates an indoor facility in Victoria, BC, and is building a 500,000 s.f. greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million s.f. to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald also owns 50% of Pure Sunfarms Inc., a partnership with Village Farms International Inc. that is converting an existing 1.1 million s.f. greenhouse in Delta, BC from growing tomatoes to growing cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Please visit www.emeraldhealth.ca for more information or contact:

Robert Hill, CFO
(800) 757 3536 Ext. #722
invest@emeraldhealth.ca

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to exercise of the Investor’s existing warrants; the development, expansion and conversion of greenhouse facilities; and the starting of adult-use cannabis market in 2018.

Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, the ability of the Company to negotiate and complete future funding transactions; variations in market conditions; and other risk factors described in the Prospectus and the Company’s other filings with the applicable Canadian securities regulators, which may be viewed at  www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.

The post Emerald Health Therapeutics Named as #1 2018 TSX Venture 50™ Performer appeared first on CannabisFN.

The post Naturally Splendid Receives $3,536,650 from the Sale of the POS-BPC Facility appeared first on CannabisFN.

Seattle, Washington–(Newsfile Corp. – February 21, 2018) – SinglePoint, Inc. (OTCQB: SING) is pleased to announce a Letter of Intent (“LOI”) with ORHub, Inc. (OTC: ORHB) to build-out a blockchain services platform for health care applications. ORHub’s surgical resource management (“SRM”) software is transforming the way hospitals handle operating room data, enabling dramatic reductions in supply chain costs. SinglePoint will design and develop for ORHub blockchain-based solutions as an add on to enhance the value of data collected by the operating room software platform. ORHub has agreed to engage SinglePoint for up to $750,000 in initial development costs. SinglePoint believes this is the first of many contracts that it will execute in the blockchain development space.

SinglePoint recently completed an annual audit, uplisted to trading on the OTCQB Venture Market and announced the addition of Venugopal Aravamudan as a board member with the intent of acquiring new business and joint technology ventures leveraging his vast network and connections built at Amazon, F5 and others. SinglePoint believes the value of the intelligent data captured at the point of care can be further unlocked through blockchain solutions that streamline and enhance the accuracy of medical records, efficiency of inventory management, and improvement of billing cycles.

“Having ORHub select SinglePoint as their solutions architect is fantastic. We are beyond excited to dig into this project and develop a truly industry-changing solution. With the commitment from ORHub to fund the project, we are in a strong position to design, develop and execute on the solution. As part of this collaboration and broader corporate initiatives in the blockchain market, we are aggressively establishing working relationships with key blockchain engineers,” states SinglePoint President Wil Ralston.

“This healthcare blockchain initiative with SinglePoint is an exciting development for us at ORHub. Our vision is to dramatically lower surgical costs, create time efficiencies while improving patient outcomes by capturing relevant surgical data and deploying this information through blockchain solutions to provide instant access for doctors, patients and hospital administrators. We believe that blockchain inspired technology will set the stage for surgical data to evolve into a new paradigm based on a shared infrastructure platform. We look forward to these advanced solutions that will enable ORHub to continue to transform the business surgery,” states Colt Melby, CEO of ORHub.

About SinglePoint, Inc. 

SinglePoint, Inc. (SING) has grown from a full-service technology provider to a publicly traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

Connect on social media at:
https://www.facebook.com/SinglePointMobile
https://twitter.com/_SinglePoint_
https://www.linkedin.com/company/singlepoint
For more information visit: www.SinglePoint.com

About ORHub, Inc.
ORHub is an advanced surgical software provider focused on real-time surgical data analytics. The Company’s suite of products serves the needs of the health care industry, hospital, patient, government and the medical device vendor. ORHub provides a cloud-based software solution that captures information before, during and after surgery, filling a void in the current surgical information infrastructure and providing the first process to capture and measure the surgical process — evolving Big Data into Intelligent Digital Data.  ORHub’s software applications allow hospitals and medical device vendors to utilize any web- enabled device to create an anatomical graphic depiction of exactly what occurs during surgery. The application automatically translates the resulting schematic into an intelligent, electronic operative report that links every detail of surgery, including implant location, surgical techniques, product usage, and all clinical parameters to create a dynamically new source of comparative information.

As a result, hospitals and surgeons can make real-time, data driven decisions to improve business profitability and the quality of patient care. This innovative technology results in hospitals under- standing costs and identifying areas of cost reductions, as well as results in increased accountability, automatic creation of comprehensive anatomic implant registries, real-time analytics, improved efficiencies, and compliance with existing government regulations. ORHub has offices in Phoenix, Arizona; Newport Beach, California; and Bellevue, Washington.

The post SinglePoint Signs LOI with ORHub to Launch Healthcare Blockchain Initiative appeared first on CannabisFN.

Vancouver, British Columbia (FSCwire) – Friday Night Inc. (Friday Night) (CSE: TGIF) (FWB: 1QF) (OTCQB: TGIFF) today announced that it has terminated its letter of intent (“LOI”) dated December 20, 2017 to acquire Body & Mind Inc. (“BAM”) in an all-stock transaction.

After careful review of the BAM transaction and current market conditions, Friday Night and Body and Mind Inc. have mutually determined the acquisition of BAM under the terms of the LOI would not be in the best interests of shareholders, and as a result, the LOI has been terminated by both parties.

Body and Mind Inc. CEO Leonard Clough commented, “Market conditions and the revised consideration proposal to our shareholders played a role in the decision to mutually terminate the proposed amalgamation plan.”

Friday Night Inc. CEO Brayden Sutton commented, “Recent market events out of our control turned the BAM acquisition into a moving target.  To keep renegotiating terms and delaying the closing date is not fair to shareholders on either side, all the while both companies may be missing other opportunities.”

About Friday Night Inc. 

Friday Night Inc. is a Canadian public company, which owns and controls cannabis and hemp-based assets in Las Vegas Nevada.  The company owns 91% of Alternative Medicine Association, LC (AMA), a licensed medical and adult-use cannabis cultivation and production facility that produces its own line of unique cannabis-based products and manufactures other third-party brands.  Infused MFG, also a 91% owned subsidiary, produces hemp-based, CBD products, thoughtfully crafted of high quality organic botanical ingredients.  Friday Night Inc. is focused on strengthening and expanding these operations within and outside of the state.

For further information please contact:

Joe Bleackley, Corporate Communications
604-674-4756
Joe@FridayNightInc.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.   Friday Night undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law or the Canadian Securities Exchange.

To view the associated document to this release, please click on the following link:
public://news_release_pdf/fridaynight02212018.pdf

To view the original release, please click here

Source: Friday Night Inc (CSE:TGIF, OTCQB:TGIFF, FWB:1QF)

Maximum News Dissemination by FSCwire. https://www.fscwire.com

Copyright © 2018 FSCwire

The post Friday Night Inc. and BAM Agree to Termination of LOI appeared first on CannabisFN.

VANCOUVER, British Columbia, Feb. 20, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (ATTBF) is pleased to announce that CannaNUMUS Blockchain Inc. (“CannaNUMUS“), a company in which Abattis has a 49% ownership interest, has entered into an agreement to acquire (the “Investment”) a 10% stake in Gabriola Green Farms (“Gabriola“) for $2.5 million. Through the Investment, Gabriola will participate in CannaNUMUS’s blockchain portfolio of cannabis companies.

Gabriola is a privately held British Columbia company that has applied for a licence to produce under the Access to Cannabis for Medical Purposes Regulations (ACMPR) on Gabriola Island, one of the gulf islands located in the Strait of Georgia off the coast of British Columbia. Gabriola Island has a consistent temperature and humidity level, which makes it well suited to greenhouse growing. Gabriola’s current facility has a production capacity of approximately 2,000 kilograms.

Through the agreement with Gabriola, CannaNUMUS has satisfied the second milestone under the Investment Agreement dated January 31, 2018 between Abattis and CannaNUMUS.

“We are very impressed with the progress and execution at CannaNUMUS,” stated Rob Abenante, President and CEO of Abattis. “We believe the collaboration between the two companies will be extremely beneficial for both entities.”

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

“Rob Abenante”
Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

Certain information set out in this news release constitutes forward-looking information. Forward-looking statements (often, but not always, identified by the use of words such as “expect”, “may”, “could”, “anticipate” or “will” and similar expressions) may describe expectations, opinions or guidance that are not statements of fact and which may be based upon information provided by third parties. Forward-looking statements are based upon the opinions, expectations and estimates of management of the Company as at the date the statements are made and are subject to a variety of known and unknown risks and uncertainties and other factors that could cause actual events or outcomes to differ materially from those anticipated or implied by such forward-looking statements. Those factors include, but are not limited to statements regarding the expected benefit to CannaNUMUS and Abattis of their collaboration, risks, uncertainties and other factors that are beyond the control of the Company, risks associated with the cannabis industry in general, rules and regulations relating to the cannabis industry, operational risks associated with development and production operations, delays or changes in plans and unanticipated costs and expenses, among others. In light of the risks and uncertainties associated with forward-looking statements, readers are cautioned not to place undue reliance upon forward-looking information. In particular, there is no assurance that CannaNUMUS and Abattis will benefit from their collaboration as expected or at all. Although the Company believes that the expectations reflected in the forward-looking statements set out in this news release are reasonable, it can give no assurance that such expectations will prove to have been correct. The forward-looking statements of the Company contained in this news release are expressly qualified, in their entirety, by this cautionary statement. Except as required by law, we do not undertake to update any forward-looking statement contained in this news release.

The post Abattis Announces CannaNUMUS Achievement of Second Milestone appeared first on CannabisFN.

BETHESDA, Md., Feb. 20, 2018 (GLOBE NEWSWIRE) — India Globalization Capital, Inc. (IGC) announced financial results for the third quarter ended December 31, 2017 for the fiscal year that ends March 31, 2018 (the “FYE2018 Q3”).

Revenue for fiscal Q3 2018 was $762,000 compared to $250,000 for fiscal Q3 2017. The increase in revenue is attributable to trading commodities related to infrastructure that is part of our legacy business.

Selling, general and administrative expenses were $507,000 for Q3 2018 as compared to $323,000 for Q3 2017.  The majority of these expenses are associated with public company costs, and the increase is attributable largely to non-cash share grants to employees, directors, and advisors. 

In Q3 2018, the Company reported a GAAP loss of $533,000 and a GAAP EPS loss of $0.02, compared to a GAAP net loss of $112,000 and a GAAP EPS loss of $0.00 for Q3 2017.   The increase in loss is attributable to a one-time non-cash gain incurred in Q3 2017 and the accounting for non-cash share grants in Q3 2018.  The non-GAAP cash loss in Q3 2018 is about $360 thousand. 

For the period ended December 31, 2017, our cash and cash equivalents was approximately $1,691,000.

“We have three major goals for 2018 a) launch Hyalolex in 10 states, b) finalize and launch Serosapse for Parkinson’s, and c) substantially reduce or eliminate debt.  Our Alzheimer’s product, Hyalolex, an industry first, is progressing as planned.  Our work on formulation and packaging is complete and we expect initial commercialization as a Complementary Alternative Medicine sold via licensed medical dispensaries in select states in the near-term, as we strive to help those diagnosed with Alzheimer’s, a disease that effects over 5.5 million in the U.S, and along with associated dementia costs the economy around $260 billion. We remain confident in the value of our phytocannabinoid therapy portfolio as we look to address key indications in the emerging medical cannabis industry,” stated Ram Mukunda, CEO.  

About IGC

IGC has two lines of business, a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry that address transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA).  The company is based in Maryland, USA.

Our website: www.igcinc.us. Twitter @IGCIR

Forward-looking Statements:

Please see forward looking statements as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission. 

Contact:
Claudia Grimaldi
301-983-0998

FINANCIAL STATEMENTS TO FOLLOW

See accompanying Notes to Condensed Consolidated Financial Statements below in this report and the Notes to the Audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.

See accompanying Notes to Condensed Consolidated Financial Statements below in this report and Notes to the Audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.

The post IGC Announces Third Quarter Financial Results Advances Hyalolex to Commercialization Stage appeared first on CannabisFN.

The post International Cannabrands Ltd. brings on KUMAA Enterprises to distribute JuJu Royal™ Products in the UK and Europe appeared first on CannabisFN.

The post OTC Markets Group Welcomes Future Farm Technologies to OTCQX appeared first on CannabisFN.

VANCOUVER, British Columbia, Feb. 15, 2018 (GLOBE NEWSWIRE) — FinCanna Capital Corp. (“FinCanna”) (CSE:CALI), have signed a binding term sheet with Gram Co Holdings LLC (“Gram Co”), subject to due diligence by FinCanna. Gram Co, based in Oakland, California, is a cannabinoid research and refinement facility focussed on the medical cannabis industry to provide B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers and numerous others in the cannabis supply chain. 

Gram Co has leased a facility in Oakland, California in which they are retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating by the end of the third quarter of 2018.  Gram Co plans to be a premier producer of bulk quantities of THC distillate and various concentrates produced via hydrocarbon-based solvent extraction. Gram Co also plans to provide white labeling services to licensed brand and infused product manufacturers who do not have direct access to compliant production facilities. Brands and manufacturers who work in conjunction with Gram Co will also be able to utilize in house distribution and marketing services as a part of operational collaborations.

Gram Co principles have extensive experience in extraction, manufacturing and business operations, and will also be bringing over their existing brand from their registered collective “California Extracts” to operate under the Gram Co family. California Extracts already has an existing industry following and market presence.

Under the term sheet, FinCanna would fund US$3 million in tranches.  In return, FinCanna will receive a tiered corporate royalty, adjusted based on revenues levels, ranging from 14% to 7.5% of Gram Co’s revenues.

FinCanna CEO, Andriyko Herchak, comments, “Statistics clearly show rapidly growing demand for high quality extracts to support the medical cannabis industry, and Gram Co, based in Oakland, is ideally positioned to service the very large Northern California market. We continue to expand our diversified royalty portfolio of investee companies, and this investment supports our thesis of best-in-class operations in the U.S. licensed medical cannabis sector.”

About FinCanna Capital Corp.

FinCanna provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on revenues.  FinCanna, led by a team of finance and industry experts, is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in U.S. legal states, with a focus on California.  For additional information visit www.fincannacapital.com and FinCanna’s profile at www.sedar.com.

FinCanna Capital Corp.
Andriyko Herchak, CEO & Director

Investor Relations:
Arlen Hansen
Kin Communications
1-866-684-6730
CALI@kincommunications.com

Forward-Looking Information

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about the market for, and effectiveness of, Gram Co’s products or services, the ability of Gram Co to expand operations and generate sales and revenues, the results of operations of Gram Co, the completion of FinCanna’s investment in Gram Co, FinCanna’s ability to fund and source future projects, and FinCanna’s ability to earn and realize revenues from its investee companies.  By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the CSE listing statement available at www.SEDAR.com and other reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the respective companies undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.

The post FinCanna Signs Binding Term Sheet with Cannabis Extraction Company in Oakland, California appeared first on CannabisFN.

Vancouver, BC, Feb. 15, 2018 (GLOBE NEWSWIRE) — Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQB: FFRMF) is pleased to announce that its subsidiary, Future Farm Maine, LLC, has received three licenses from the State of Maine for the cultivation of industrial hemp in 2018. Future Farm Maine received one license for each of its Amity and Hersey farms, as well as one for the Belfast processing facility.

Mr. Bill Gildea, CEO of Future Farm comments, “We are thrilled to have received these three licenses to operate our industrial hemp business in Maine and are excited to build our high value, vertically integrated industrial hemp farm and CBD oil production facility in 2018.”

As recently announced, the Company signed a lease agreement for an initial 12,960 sq. ft. of space in a 60,000 sq. ft. building, with an option to expand or buy the building.  Future Farm Maine will use the Belfast building to germinate 250,000 hemp seeds over the next few months, which then will be planted to meet the summer growing season at the Amity and Hersey farms. With over 100 organic certified acres ready to plant and an additional 1,000 acres available for expansion, Future Farm Maine is poised to be the largest hemp farm in the North East.

Future Farm Maine plans to use feminized seeds of the highest quality, CBD strains in the industry that test in compliance of hemp laws of having .03% THC or less while averaging 15% CBD. The hemp seeds will also be germinated under the Company’s LED grow lights, which will save on electricity costs and further leverage its in-house technology. Once harvested, the hemp will be dried and further refined using Future Farm’s high output oil processing equipment creating both CBD oil and high value isolate for making edibles, creams and lotions.

Future Farm is also pleased to announce that it has engaged Mr. Zachary Lapan to oversee the Company’s Maine cultivation and processing operations. Mr. Lapan has worked closely with Derek Ross providing operational oversight for ten years. Mr. Lapan has deep community and agricultural ties to Maine, and is excited to provide operational expertise in Future Farm Maine’s portfolio of projects.

“Growing hemp in northern Maine requires local, agricultural and climate expertise,” comments Derek Ross, President of Cannatech and Future Farm’s joint venture partner in Maine. “Mr. Lapan is a successful, seasoned hemp farmer and I’m excited that he has joined the team.”

Comments Mr. Lapan, “It is time to get to work! This is going to be fun and I’m excited to be on the forefront of the hemp industry here in Maine. We have an aggressive schedule to develop our propagation facility and we will hire the best and most talented local resources to get the job done.”

The market for CBD is poised for expansion due in part to the FDA’s acceptance of a New Drug Application submitted by GW Pharmaceuticals plc for Epidiolex®, a drug containing CBD. Three Goldman Sachs analysts projected 2025 worldwide sales of US$2.2 billion for Epidiolex®, with more than half (56 percent) of the sales coming from off-label use. Sales of CBD in the United States across the hemp-derived, marijuana-derived and pharmaceutical industries is projected to reach $1.1 billion by 2020, according to Hemp Business Journal.

The Company also confirms that the Board of Directors has approved the cancellation of 3,875,000 incentive stock options currently exercisable at $1.24CDN.

 On behalf of the Board,

 Future FarmTechnologies Inc.

 William Gildea, CEO & Chairman

About Future Farm

Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land.  The contained system provides many other benefits including 90% less water, fertilizer and land used, less travel costs, seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability. The Company also utilizes a leading cannabis oil extraction technology, which enables the Company to process 20lbs/hour of cannabis plant to yield approximately 908 grams/hour of oil.

The post Future Farm Receives Three Industrial Hemp Licenses for 2018 appeared first on CannabisFN.

TORONTO, ON / ACCESSWIRE / February 15, 2018 / Ehave, Inc. (EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced that the the Company will expand its informatics solution to include Blockchain Technology. With careful consideration and research into the market needs of mental healthcare and medical cannabis, the Company sees an opportunity to implement Blockchain solutions that are driven from a patient focused strategy, rather than a technology first approach. IDC (Jan 2018) is predicting that global spend on blockchain will reach $2.1 billion in 2018, and that regulator’s positive comments about blockchain will “help accelerate demand in regulated industries such as … healthcare”.

So far, Blockchain has primarily been used by cryptocurrency implementations to provide a decentralized consensus platform for validating financial transactions. Ehave is looking at applying and improving the principles behind current Blockchain technology to allow patients greater control over their health record, while providing a decentralized mechanism for trusted stakeholders to contribute and access data for the benefit of the patient. The Ehave private Blockchain framework strategy leverages the trust in its health stakeholders to:

• Improve on the algorithm used to validate and reach consensus on all transactions involving the patient record.
• Provide support for the trusted stakeholders to publish new data to the patient record and to notify the patient when that data becomes available.
• Support smart contracts, allowing patients the ability to control what portions of their health record are available to which parties, and for what period of time (ideal for supporting formal clinical trials and observational studies).
• Provide a patient and stakeholder portal that retrieves and displays data according to the access granted by the Blockchain.

Combined, these will serve as the foundational elements for the secure and high integrity exchange of data amongst patients, clinicians, researchers, therapeutic companies and licensed producers from molecule/seed to sale to patient to efficacy and back.

Lead by Ehave CTO Dave Goyette, with over 30 years of health technology experience, Ehave will leverage its expertise in health data privacy and security to establish itself as a leader in the development and use of Blockchain in mental health and medical cannabis. Over the next six months, the Company will be formalizing partnerships with technology providers, consulting organizations, and consortiums to integrate to Ehave’s established informatics platform, which already houses 25,000 patient records.

“Ehave’s informatics platform was built to capture high quality clinical data throughout the patient journey, something that is missing in both mental healthcare and medical cannabis. We believe that the timing is right to ensure a standardized mechanism exists to allow data sharing while ensuring patient privacy and data security,” says Prateek Dwivedi, CEO of Ehave. “During my tenure as chief information officer at Mount Sinai Hospital and leading the Cancer Informatics Program and Princess Margaret Cancer Centre in Toronto, data sharing in healthcare was always a challenge to get right. We have the platform, customers and patients to make a real difference.”

About Ehave, Inc.

Ehave is empowering the mental healthcare community with a next generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with MedReleaf. For more information, visit https://www.ehave.com/.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

The post Ehave Enters Blockchain Market for Secure Access of Patient Data in Mental Healthcare and Medical Cannabis appeared first on CannabisFN.

SEATTLE, Feb. 14, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — SinglePoint Inc. (SING) provides shareholder update on recent OTCQB up-list, company overview and adding key board member to help guide company technology initiatives. SinglePoint is currently engaged with auditor to complete 2017 audit and become fully reporting soon. Becoming fully reporting should increase the exposure of SinglePoint to institutional investors for direct investment as well as through the open market. In addition to this the company looks to increase transparency and credibility for its shareholders and ultimately increase the value of SinglePoint.

A requirement of the company’s move to the OTCQB Venture Markets was to add an additional board member. SinglePoint has added previous Amazon General Manager and current F5 Networks Senior Vice President Venugopal Aravamudan. Mr. Aravamudan has a 25+ years tenure in the technology sector growing and leading significant businesses at companies such as Microsoft, VMware, Amazon and now F5 networks Inc. Most recently,at Amazon, Mr. Aravamudan ran a significant portion of the Amazon Web Services Relational Database Systems services managing large teams and significant revenues. Currently he is Senior Vice President and General Manager at F5 Networks and responsible for their next generation cloud services offerings.

“I am excited to join the board at SinglePoint and help them accelerate leveraging technology such as Blockchain and Cloud Computing to deliver business services at a large scale. Singlepoint has great assets and people to help them build differentiated and global capabilities and I look forward to helping them get to this next level.”

Management believes bringing on such a high-powered board member that is well connected both locally and internationally will help lead SinglePoint to its overall company goals. Mr. Aravamudan has committed to making accretive introductions to the company leveraging cloud computing capabilities that will accelerate the capability for Singlepoint to deliver BlockChain enabled solutions.

“We are very happy Mr. Aravamudan has joined us. This gives us the expertise we need for accelerating the right set of technology based Joint Ventures, Acquisitions and other interesting Big Data plays that unlock the potential for blockchain applications,” states SinglePoint President Wil Ralston.

The company has started video updates and looks to release these as updates permit. Follow this link to see the inaugural video. Note – Since the filming of this segment SinglePoint has successfully up-listed to the OTCQB Venture Markets. SinglePoint Inaugural Video Update

About SinglePoint, Inc.

SinglePoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base. Through its subsidiary company SingleSeed, the company is providing products and services to the cannabis industry.

Connect on social media at:
https://www.facebook.com/SinglePointMobile
https://twitter.com/_SinglePoint_
https://www.linkedin.com/company/singlepoint
For more information visit: www.SinglePoint.com

Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

The post In Route to Becoming Fully Reporting, SinglePoint Up-Lists to OTCQB and adds Former Amazon GM as Additional Board Member appeared first on CannabisFN.

SACRAMENTO, Calif., Feb. 13, 2018 /PRNewswire/ — Smart Cannabis Corp, (SCNA), announced today it has significantly broadened its joint venture agreement with Singlepoint, Inc., (SING) providing SinglePoint with the rights to sell Smart Cannabis’ Smart by Design greenhouses. This provides Smart Cannabis additional footprint to grow its base and SinglePoint access to some of the best greenhouses on the market.

Under terms of the agreement, SinglePoint will be have an exclusive agreement on Smart Cannabis products sold and installed within Arizona, which includes the company’s line of SMART by Design™ automated greenhouse systems including the SMARTAPP automation software product, and the soon-to-be-released “Track and Trace Software System.” Arizona is one of the nation’s largest MMJ Markets and show no signs of slowing down. Most recently bipartisan legislation was introduced through House Concurrent Resolution 2037 that would allow legalized marijuana of one ounce or less for personal use. According to Phoenix New Times and Arizona Department of Health Services, medical cannabis consumption was up over 50 percent in Arizona in 2017, with over 43 million tons sold. Sales also soared in 2017, reaching an estimated $387,000,000, according to AZ Central.

Smart Cannabis CEO John Taylor exclaimed, “Expanding into the Arizona market will increase our growth potential dramatically and we’re thrilled to be doing this with a reliable partner such as SinglePoint.” To his point, SinglePoint President Wil Ralstonstated, “We are excited about this opportunity. The company has some great connections in Arizona and some soft commitments on potentially purchasing some greenhouses from us. Additionally we are excited for the Track and Trace Software we believe with our development team we can really ramp this up and introduce it to the relationships we have here.”

In accordance with a previous agreement, the SMARTAPP will soon include the bitcoin payment gateway that the companies are actively developing to make payments transactions easier for all parties involved.

Smart Cannabis (OTC PINK: SCNA) is a public equity corporation advancing the agriculture and cannabis industries and growing through acquisition, strategic alliances, and proprietary intellectual property. The company’s wholly owned subsidiary, Next Generation Farming Inc., provides turnkey, automated, commercial greenhouses systems that efficiently improve yields and decrease water consumption for cultivators of organic food and cannabis crops. The company websites are http://smartcannabis.com and http://nextgen.farm.

Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. The company may make forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates that reflect the company’s best judgment based upon current information. All investments involve risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.

The post Smart Cannabis Expands Joint Venture with SinglePoint appeared first on CannabisFN.

The post Maricann Hires Experienced VP of Sales and Marketing appeared first on CannabisFN.

VANCOUVER, British Columbia, Feb. 12, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce the sponsorship of a research study in partnership with Mitacs to explore the development of nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil. The research and development work will be led by scientists from Abattis and the Faculty of Land and Food Systems at the University of British Columbia (“UBC”).

Mitacs is a national, not-for-profit organization that has designed and delivered research and training programs in Canada for 18 years working with 60 universities, thousands of companies, and both federal and provincial governments.

In addition to the R&D work on cannabinoid-rich THC-free hemp extracts, scientist from Abattis and UBC’s Faculty of Land and Food Systems will work to create delivery platforms with increased stability and bioavailability.

“Abattis is very pleased to begin working with premiere scientists from UBC, and in the University’s first-class cell-culture research facility,” said Rob Abenante, President and CEO of Abattis.

Mr. Abenante added: “Our partnership will focus on developing nanoparticle-based delivery platforms since nanoparticulation allow more efficient and faster absorption of active compounds such as cannabinoids and terpenes, reducing the typical losses associated with gut absorption. This new development is part of our overall strategy to provide high-end extracts to our manufacturing partners and to support the development of unique finished products.”

“Our research will help develop stable encapsulated hemp-oil formulations for delivering the medicinal ingredients of cannabis orally, but without the harmful effects of smoking. Stable hemp extracts, with tailored profiles of cannabinoids and terpenes, could be used for targeted treatment of patients and help them lead a healthy lifestyle,” said Dr. Anubhav Pratap Singh, Assistant Professor, Food Nutrition and Health Program, Faculty of Land and Food Systems, UBC.

The University of British Columbia’s Faculty of Land and Food Systems has world-class research laboratories with modern analytical instrumentation. UBC consistently ranks among the Top 40 universities in the world, and among the Top 20 public universities in the world.

“Securing this partnership provides additional support to our Research and Development strategy to prepare a new class of cannabis and hemp finished products with high bioavailability, stability and shelf-life. This technology will become a core driver for a future line of formulations to be used under white-label, and in-house finished products,” said Dr. David Galvez, Senior Science Advisor of Abattis. 

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.

ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,

“Rob Abenante”
Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 336-0881 or at news@abattis.com. 

FORWARD LOOKING INFORMATION 

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the research and development to be performed between the Company and UBC; the success of its formulation efforts on proprietary cannabinoid oils; the success of the marketing and sales of its proprietary formulations; the bioavailability and product efficacy of the results of the research conducted.   Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including that the partnership with UBC or the grant will result in useful product developments.  Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.

The post Abattis awarded a Mitacs grant for R&D of nanoemulsified cannabinoid-rich hemp oil in conjunction with food scientists from the University of British Columbia appeared first on CannabisFN.

Vancouver, British Columbia, Feb. 08, 2018 (GLOBE NEWSWIRE) — Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE:FFT) (FFRMF) is pleased to announce that is has closed on the previously announced joint venture between Future Farm and TCG Investments, LLC, owners of the Clinica Verde brand of medical cannabis dispensaries (“Clinica Verde”). Future Farm has purchased a 40% ownership interest and a 50% economic interest in FFPR, LLC, a Puerto Rican limited liability company, which holds five pre-qualifications for medical dispensary licenses (the “Licenses”). The five medical cannabis dispensaries in Puerto Rico will be operated under the Clinica Verde brand, which has already established itself as the leading medical cannabis dispensary operator in Puerto Rico. Currently, Clinica Verde has five operating dispensaries and with this partnership the brand will have ten in total.

Link To Clinica Verde Dispensaries:  Clinica Verde Homepage

Future Farm is investing and partnering with the most experienced operator in Puerto Rico, thereby leveraging their brand and dispensary experience on the island.  This investment is part of Future Farm’s plan of continuing to create a diversified portfolio of cannabis investments for its shareholders.

“Our existing stores are located in high-traffic locations, and ever since our launch in February 2017 we have enjoyed sustained sales growth. We are excited to be working with the Future Farm team and expand our presence to ten stores in Puerto Rico, creating jobs and offering our patients the highest level of service,” says Ramón Ortiz, CEO of Clinica Verde. “The patient registration process was recently simplified and is now quicker and more accessible to all. We believe we will be able to start building out the new dispensary locations this year and look forward to a 2018 opening.” 

Medical marijuana is legally used in Puerto Rico to address more than a dozen conditions, including Alzheimer’s, cancer, Lou Gehrig’s disease, Parkinson’s, rheumatoid arthritis, Crohn’s disease, epilepsy and more. On October 6, 2017, Puerto Rico’s Department of Cannabis’ board approved allowing patients to go to any open clinic, regardless of the dispensary they had been assigned.

“We’re pleased about the revenue opportunities these five major dispensaries open up to us as we provide medical marijuana patients with legal, consistent, pure flower, edibles and concentrates,” says Bill Gildea, CEO of Future Farm Technologies.  “Puerto Rico, with a population of almost 3.5 million residents and another 4 million annual visitors, is an exciting, new market for Future Farm.” The local population compares well to other states that have legal cannabis. By way of example: Colorado has a population of about 5,540,545, Utah 3,051,217, Arizona, 6,931,071 and Nevada has 2,940,058.

Puerto Rico’s MMJ industry has full governmental support, which means the island could become a cannabis tourism mecca of the Caribbean. Importantly, the island’s cannabis law includes a reciprocity policy that allows dispensaries to serve patients whom are visiting for business or just on vacation, as long as they hold a medical marijuana card from their home state.

As consideration for the 40% ownership interest and a 50% economic interest, Future Farm agrees to pay USD$865,000 (USD$346,000.00 to TCG and USD$519,000.00 to FFPR, LLC’s sole member.)

The Company is also pleased to announce that it is granting incentive stock options to certain directors, officers, employees and consultants to acquire a total of 3,487,500 common shares at an exercise price of $0.96CDN, which was the closing price on February 7, 2018.  As per the Company’s Stock Option Plan, the options expire five (5) years from the date of grant and vest immediately. 

For further information, contact William Gildea, Director, at 617.834.9467.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, CEO & Chairman

About Clinica Verde

TCG Investments, LLC (“TCG”) is a limited liability company headquartered in San Juan, Puerto Rico. TCG currently operates four medical cannabis dispensaries under the Clinica Verde brand in the municipalities of San Juan, Caguas and Humacao. All Clinica Verde dispensaries are located in high-traffic areas and are distinguished by their modern design and personalized service. Clinica Verde features medical cannabis products from all major licensed medical cannabis manufacturers in Puerto Rico. Under the proposed Joint Venture, TCG will operate 10 medical cannabis dispensaries in Puerto Rico by mid-2018.

About Future Farm

Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land.  The contained system provides many other benefits including 90% less water, fertilizer and land used, less travel costs, seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability. The Company also utilizes a leading cannabis oil extraction technology, which enables the Company to process 20lbs/hour of cannabis plant to yield approximately 908 grams/hour of oil.

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com, which caters to B2B customers, is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com, which caters to both large and small agriculture green houses and controlled cultivation centers.

The Company recently acquired the exclusive right to use a patented, augmented reality (AR) technology in the cannabis industry. The Company will work with its partner to merge AR and ad-tech with the cannabis industry through the CannaCube LiveTM platform.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts 
responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. 

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

The post Future Farm Acquires Stake in Five Cannabis Dispensary Licenses in Puerto Rico appeared first on CannabisFN.

The post Abattis Completes Investment in CannaNUMUS Blockchain and Announces CannaNUMUS’s Achievement of a Significant Milestone appeared first on CannabisFN.